Tetherex licenses adenovirus vaccine platform from Mayo Clinic

By The Science Advisory Board staff writers

July 6, 2021 -- Tetherex Pharmaceuticals has obtained an exclusive worldwide license for the development and commercialization of a novel single-cycle adenovirus vaccine platform from the Mayo Clinic. The platform will be used to target multiple infectious diseases beginning with a COVID-19 vaccine.

The single-cycle adenovirus platform was developed to enhance the expression of target antigens to amplify immune responses to infectious disease targets. Tetherex is investigating the technology in a phase I open-label study designed to assess the safety, reactogenicity, and immunogenicity of a single-cycle adenovirus vaccine candidate against COVID-19.

The trial is expected to enroll up to 80 healthy volunteers and includes both a single ascending dose group and multiple dose group via either intramuscular or intranasal administration.

Financial details regarding the license agreement were not disclosed.

Sorrento subsidiary to develop ADC cancer therapies
Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for...
A bright new tactic in the fight against cardiovascular disease
A new system using reporter proteins has been developed by researchers at Carnegie, Johns Hopkins University, and the Mayo Clinic that uses high-throughput...

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter